H.R.3264 - American Life Sciences Competitiveness Act of 2007110th Congress (2007-2008)
|Sponsor:||Rep. Schwartz, Allyson Y. [D-PA-13] (Introduced 07/31/2007)|
|Committees:||House - Ways and Means|
|Latest Action:||08/02/2007 Sponsor introductory remarks on measure. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.3264 — 110th Congress (2007-2008)All Information (Except Text)
Introduced in House (07/31/2007)
American Life Sciences Competitiveness Act of 2007 - Amends the Internal Revenue Code to allow biomedical research corporations to: (1) engage in investment activity involving shifts in ownership without incurring limitations on net operating loss carryforwards; (2) claim a full research and development tax credit for contract research expenses (currently, limited to 65%); (3) claim a business tax credit for 20% of eligible countermeasures research expenses (for biomedical threats); and (4) claim a tax-free rollover of gain from stock sales reinvested in another biomedical research corporation.
Expands the tax credit for clinical testing expenses for drugs to treat rare diseases (orphan drugs) to include expenses incurred after an application is made to the Food and Drug Administration (FDA) but before receipt of an orphan drug designation.
Allows individual taxpayers a 20% tax credit for equity investments in small biomedical research firms engaged in incubational research (i.e., research conducted prior to large-scale clinical trials).